Clarifying the Role of PARP Inhibitors in Ovarian Cancer

Clarifying the Role of PARP Inhibitors in Ovarian Cancer

New Evidence, New Perspectives

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

Join our expert faculty as they discuss poly-(ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer, including rationale and supporting clinical evidence for the use of PARP inhibitors in advanced ovarian cancer. There will be a particular focus on the latest emergent data in newly diagnosed disease and the implications in terms of future clinical application. Please join us and come with your most pressing questions.

ESMO 2019 Industry Satellite Symposium

Date and Location

Sunday, 29 September 2019
18:30 – 20:00

Pamplona Auditorium, Hall 2
Fira Gran Via
Barcelona, Spain



Sunday, 29 September 2019
18:30 – 20:00



Barcelona, Spain



1.5 Continuing Professional Development (CPD) Credit(s)

18:30 Introduction: The Challenges and Opportunities in Treating Advanced Ovarian Cancer
Ana Oaknin, MD, PhD
18:35 Why, When, and in Which Patients PARP Inhibition Makes Sense: Linking the Biology, the Disease, and the Treatment
Jonathan A. Ledermann, MD, FRCP, FMed Sci
18:45 PARP Inhibitors in Relapsed Platinum-Sensitive Disease: Where Are We?
Kathleen Moore, MD
19:05 PARP Inhibitors in Newly Diagnosed Ovarian Cancer: What Is the Evidence?
Philipp Harter, MD, PhD
19:25 Clarifying the Paradigm for PARP Inhibitors: Expert Perspectives
Panel discussion
19:55 prIME Points™
Ana Oaknin, MD, PhD
20:00 Adjourn



  • Ana Oaknin, MD, PhDVall d’Hebron Institute of Oncology
    Barcelona, Spain
  • Faculty

  • Philipp Harter, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Jonathan A. Ledermann, MD, FRCP, FMed SciUCL Cancer Institute
    UCL Cancer Trials Centre
    London, United Kingdom
  • Kathleen Moore, MDStephenson Cancer Center
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma, United States

This educational activity is intended for medical oncologists, gynecologists, surgeons, and other healthcare professionals based outside the United States who are involved in the management of ovarian cancer.

After successful completion of this educational activity, participants should be able to demonstrate:

  • Increased knowledge regarding the
    • Biological and clinical rationale for PARP inhibitors in advanced ovarian cancer
    • Emerging data for PARP inhibitors in newly diagnosed advanced ovarian cancer
    • Implications for practice of emerging data for PARP inhibitors in newly diagnosed advanced ovarian cancer
  • Greater confidence in their ability to
    • Optimally integrate PARP inhibitors into the management of their patients with advanced ovarian cancer
    • Ascertain the role of PARP inhibitors in advanced ovarian cancer in clinical practice

This educational activity is supported by a grant from AstraZeneca Pharmaceuticals LP.

Continuing Education

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credit(s) (CPD).


This activity is provided by prIME, a Medscape Oncology Company.


Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.